| ORMP |
Oramed Pharmaceuticals Inc. |
72%
|
o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, incl… |
| ORMP |
Oramed Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from ORMP graph: Reciprocal relationship from SMNR graph: o other available therapies. Health Technology Assessment (“HTA”) of medicinal products is becoming an increasingly c… |
| SCLX |
Scilex Holding Company |
72%
|
Reciprocal relationship from SCLX graph: Reciprocal relationship from SMNR graph: Reciprocal relationship from SCLX graph: Reciprocal relationship from SMNR graph: Reciprocal relationship from SCLX g… |
| SCLX |
Scilex Holding Company |
72%
|
celled in exchange for shares of Common Stock and options to purchase Common Stock, F- 7 Table of Contents SEMNUR PHARMACEUTICALS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited… |
| SCLXW |
SCLXW |
72%
|
celled in exchange for shares of Common Stock and options to purchase Common Stock, F- 7 Table of Contents SEMNUR PHARMACEUTICALS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited… |
| SCLXW |
SCLXW |
72%
|
Reciprocal relationship from SCLXW graph: Reciprocal relationship from SMNR graph: celled in exchange for shares of Common Stock and options to purchase Common Stock, F- 7 Table of Contents SEMNUR PH… |
| SNYNF |
Sanofi |
72%
|
in current treatments, ways to highlight these prior to launch, and the expectations for the new treatments. • Product positioning : Position the product by highlighting physician feedback on the pro… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SMNR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SMNR graph: Reciprocal relationship from SNYN… |
| CMS-HEALTH-RESOURCES |
CMS-HEALTH-RESOURCES |
62%
|
ot be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations, FDA debarment, exclusion from government-funded healthcare programs or other … |
| FORTIS-ADVISORS-LLC |
FORTIS-ADVISORS-LLC |
62%
|
. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements fo… |
| JW-INVESTMENT-MANAGEMENT-COMPANY-LIMITED |
JW-INVESTMENT-MANAGEMENT-COMPANY-LIMITED |
62%
|
g $ 54.2 million, was converted into 5,423,606 shares of Legacy Semnur Series A preferred stock. At Closing, such shares were exchanged for 5,423,606 shares of Series A Preferred Stock and 542,361 sh… |
| LFCR |
Lifecore Biomedical, Inc. |
62%
|
Reciprocal relationship from LFCR graph: Reciprocal relationship from SMNR graph: ients’ willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and • our ability… |
| LIFECORE-BIOMEDICAL-LLC |
LIFECORE-BIOMEDICAL-LLC |
62%
|
ients’ willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and • our ability to compete with other treatments. We do not have complete control over many of th… |
| MERGER-AGREEMENT-DENALI-CAPITAL-GLOBAL-INVESTMEN |
MERGER-AGREEMENT-DENALI-CAPITAL-GLOBAL-INVESTMEN |
62%
|
g $ 54.2 million, was converted into 5,423,606 shares of Legacy Semnur Series A preferred stock. At Closing, such shares were exchanged for 5,423,606 shares of Series A Preferred Stock and 542,361 sh… |
| SCILEX-GROUP |
SCILEX-GROUP |
62%
|
rs of our Common Stock. ” Furthermore, the interests of Scilex may not be aligned with those of other stockholders and this could lead to actions that may not be in the best interests of our other st… |
| SECURITIES-INVESTOR-PROTECTION-CORPORATION |
SECURITIES-INVESTOR-PROTECTION-CORPORATION |
62%
|
it Insurance Corporation or the Securities Investor Protection Corporation. If our 97 digital assets are lost under circumstances that render another party liable, there is no guarantee that the resp… |
| SIGMA-MERGER-SUB-INC |
SIGMA-MERGER-SUB-INC |
62%
|
. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements fo… |
| SORRENTO-THERAPEUTICS-INC |
SORRENTO-THERAPEUTICS-INC |
62%
|
. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements fo… |
| VSTOCK-TRANSFER-LLC |
VSTOCK-TRANSFER-LLC |
62%
|
rs of our Common Stock. ” Furthermore, the interests of Scilex may not be aligned with those of other stockholders and this could lead to actions that may not be in the best interests of our other st… |
| XU-FUTURETECH-CAPITAL-LLC |
XU-FUTURETECH-CAPITAL-LLC |
62%
|
rs of our Common Stock. ” Furthermore, the interests of Scilex may not be aligned with those of other stockholders and this could lead to actions that may not be in the best interests of our other st… |
